Targeting SV2A for discovery of antiepileptic drugs
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Proepileptic phenotype of SV2A‐deficient mice is associated with reduced anticonvulsant efficacy of levetiracetamEpilepsia, 2009
- Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2ABritish Journal of Pharmacology, 2008
- The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetamProceedings of the National Academy of Sciences, 2004